Full-Time
Senior Project Manager
Veeva Systems
10,001+ employees
Cloud-based quality, regulatory, and claims management
Compensation Overview
$75k - $115k/yr
Company Historically Provides H1B Sponsorship
Lyndhurst, NJ, USA
In Person
On-site in Lyndhurst, New Jersey; may require travel for customer meetings.
Bachelor's
 Business & Strategy (1) |
|---|
Get referred to Veeva Systems
See people who can refer or advise you
- B.S. or B.A. degree or equivalent experience
- PMP Certification
- 5-8 years of project management experience in software implementation, with a strong background in project management and customer-facing delivery
- Demonstrated success leading technology implementations
- Pharmaceutical Speaker Bureau experience is a plus
- Pharmaceutical Event Planning experience is a plus
- Strong analytical and problem-solving skills
- Professional and clear oral and written communication
- Exceptional communication and stakeholder management skills, with the ability to translate business needs into actionable project plans
- Demonstrate ability to work in a fast-paced environment, and/or multitask often to meet fluctuating customer/company priorities
- Possesses strong leadership presence and are entirely comfortable holding people accountable to ensure project success and timely execution.
- Strong working knowledge of Microsoft Office (Excel, Word, PowerPoint), Google Suite of Applications, Smartsheet
- Must be able to travel and work onsite for customer meetings
- Lead the end-to-end delivery of solutions, from project initiation through successful go-live and continuous improvement phases
- Facilitate delivery and execution of new customer implementations, managing multiple workstreams, dependencies, enforces timelines, budget and quality
- Monitor project progress, proactively manage risks and issues, and ensure projects stay on schedule and within scope
- Ensure gaps, risks and timelines are clearly communicated with clear follow-up to task owners until completion.
- Consistent review of overall project timeline and identify and communicate risks to project completion timeline clearly and with detailed steps to ensure success.
- Build and nurture strong, lasting relationships with customers and internal teams.
- Serve as the primary liaison between customer stakeholders and Veeva, addressing needs, resolving concerns, and ensuring satisfaction.
- Guide customers in adopting industry and Veeva best practices, with a focus on long-term value realization and process optimization
- Understand project objectives, timelines, deliverables, challenges, and opportunities to deliver tailored solutions.
- Proactively provide updates to timeline, project status, risks and gaps.
- Partner with cross-functional teams to ensure seamless delivery of services and solutions.
- Facilitate communication between internal departments to align on project goals and deliverables.
- Familiar with health sciences and regulated environments
- Maintain current knowledge of appropriate regulations, e.g., OIG, PhRMA Code
- Fundamental knowledge of Veeva Commercial Cloud Product Suite including by not limited to Veeva CRM, Veeva Vault, Events Management, and Engage
- Ability to work and thrive in a team atmosphere
- Positive attitude and maintain a “Whatever it Takes” attitude
Veeva Systems provides cloud-based software that helps consumer goods and chemical companies manage quality, regulatory compliance, and advertising claims. The platform works by connecting different departments—from the supply chain to marketing—to provide a single source of data that tracks a product's journey and ensures it meets safety standards. Unlike competitors that offer general business tools, Veeva specializes in navigating the highly complex regulations originally found in the life sciences sector and applies that specific expertise to other regulated industries. The company's goal is to help businesses bring safe, sustainable, and compliant products to market faster by providing end-to-end visibility and traceability.
Company Size
10,001+
Company Stage
IPO
Headquarters
Pleasanton, California
Founded
2007
Get referred to Veeva Systems
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q1 2027 revenue reached $882.9 million on June 3, 2026, beating estimates.
- Copli became Veeva Falcon MLR on June 23, 2026, expanding AI monetization.
- Veeva EHS launched June 25, 2026, adding a new Quality Cloud wedge.
What critics are saying
- Salesforce CRM migration pressure remains explicit in Veeva's 2026 10-K.
- Veeva Falcon AI invites scrutiny if outputs fail GxP review or misstate regulated content.
- A major security breach would damage trust, trigger lawsuits, and stall renewals quickly.
What makes Veeva Systems unique
- Veeva Vault CRM deepens lock-in across regulated life sciences workflows and data.
- Veeva Falcon MLR automates compliant content review inside PromoMats, not a standalone tool.
- UCB's June 2026 Safety Suite rollout shows enterprise-grade switching costs and implementation depth.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Parental leave
PTO
Free food
Health, dental, & vision insurance
Gym membership reimbursement
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Vulcan Value Partners added Veeva Systems to its All-Cap strategy in Q2 2026, describing the company as the dominant vertical market software system of record for the life sciences industry. The investment firm noted that Veeva's customers rely on its platform to run their entire business, from drug development and regulatory approval to manufacturing, selling, and marketing. Veeva grew revenue and EBIT by 16% and 24% respectively in 2025 and maintained strong momentum into 2026. Despite these results, the stock fell nearly 20% year-to-date through end-June, moving in sympathy with the broader application software sector. On 29 July 2026, Veeva shares closed at $207.91, giving it a market capitalisation of $33.77 billion. According to data, 62 hedge funds held Veeva at the end of Q1, down from 75 in the previous quarter.
IDDI joins Veeva CRO Partner Program to expand eClinical technology offerings for clinical trials. July 17, 2026. BRUSSELS; RALEIGH, N.C.; July. 16, 2026 - IDDI today announced it has joined the Veeva CRO Partner Program, further expanding its eClinical technology ecosystem to support sponsors running clinical trials of all sizes and complexities. As a leading provider of biometrics services, including biostatistics, data management, RTSM, and strategic consulting, IDDI is committed to helping sponsors select the technologies that best fit their protocol requirements and operational needs. Through this partnership, IDDI will expand the range of eClinical solutions available to its customers by adding Veeva Clinical Data applications, including Veeva EDC, Veeva DQS, Veeva eCOA, and Veeva RTSM. By combining scientific expertise with advanced technology solutions, IDDI helps sponsors build efficient, scalable clinical trial strategies that support high-quality data collection, streamlined study execution, and successful clinical outcomes. "Sponsors need the flexibility to build clinical technology ecosystems that support their unique study requirements," said Tara Kervin, Chief Operating Officer at IDDI. "By joining the Veeva CRO Partner Program, we are expanding our eClinical technology portfolio with Veeva's EDC, DQS, eCOA, and RTSM solutions. Together, we can better align technology with protocol design, giving sponsors greater choice while helping them execute studies more efficiently and confidently." The partnership reflects a shared commitment to providing life sciences organizations with modern, connected solutions that support efficient trial execution and enable teams to manage increasingly complex studies with confidence. About IDDI IDDI is a trusted clinical data science partner. With 35+ years of research-driven experience, IDDI Inc. combine therapeutic expertise, biostatistical leadership, and regulatory insight to mitigate risk from design to registration and beyond. IDDI Inc. deliver uncompromising excellence in biostatistics, strategic consulting, clinical data management, IDMCs, and supporting eClinical technologies, because when every data point represents a patient, perfection is the only option.
Stifel has reiterated its Buy rating and $230 price target on Veeva Systems following the company's acquisition of Copli, an agentic medical, legal and regulatory solutions firm. Veeva rebranded the acquisition as Veeva Falcon MLR, claiming the solution can eliminate 70% or more of manual MLR labour within five years. The system conducts compliance checks on promotional and medical materials against approved labels and local regulations. Separately, Veeva launched Veeva EHS on 25 June, a new environmental, health and safety application within its Veeva Quality Cloud. Veeva Systems delivers industry cloud solutions for life sciences, offering software, AI, data and consulting services.
Veeva Systems has announced Veeva EHS, a new environmental, health and safety application within Veeva Quality Cloud. The solution enables manufacturing and testing sites to identify, manage and mitigate operational and environmental risks whilst ensuring global compliance readiness. Veeva EHS integrates directly with Veeva QMS and Veeva Training, allowing safety events to automatically trigger quality deviations and assign targeted retraining. This eliminates duplicate data entry and streamlines workflows across the entire EHS process. The application provides real-time insights into leading risk indicators and uses intelligent automation to improve site efficiency. Planned for early adopter availability in August 2026, Veeva EHS represents a significant advancement in how organisations manage environmental, health and safety responsibilities through a unified platform.
Veeva introduces new EHS application for proactive risk management and intelligent automation. June 24, 2026 Environmental, health, and safety solution is part of Veeva Quality Cloud and will deliver real-time insights and streamlined workflows PLEASANTON, CA - June 25, 2026 - Veeva Systems (NYSE: VEEV) today announced Veeva EHS, a new application in Veeva Quality Cloud for environmental, health, and safety. With Veeva EHS, manufacturing and testing sites can proactively identify, manage, and mitigate operational and environmental risks and ensure global compliance readiness. "A modern EHS solution that simplifies processes through unified data and a seamless user experience across the entire EHS workflow can significantly improve site efficiency," said Bobbie Grant, global senior EHS manager, Thermo Fisher Scientific. "It is exciting to see Veeva build an advanced solution that can not only maintain data integrity today but also provide the foundation for AI-driven capabilities that can further reduce risk over time." Veeva EHS will provide an intuitive way to report safety incidents on the spot and manage investigations from start to finish. Because it connects directly with Veeva QMS and Veeva Training, a safety event can automatically trigger a quality deviation and assign targeted retraining, eliminating duplicate data entry and ensuring compliance. "Delivering an advanced, automated approach to managing environmental, health, and safety processes, Veeva EHS will free up time for EHS teams and ensure quick and accurate execution," said Beth Tanner, vice president, Veeva EHS strategy. "Organizations replacing legacy EHS systems with a unified platform will gain real-time transparency into leading indicators of risk for more informed decisions and a proactive approach to prevention." Planned for early adopter availability in August 2026, Veeva EHS marks a significant step in how organizations manage environmental, health, and safety responsibilities with increased transparency and intelligent automation. About Veeva Systems Veeva delivers the industry cloud for life sciences with software, AI, data, and consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com. Veeva Forward-Looking Statements This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of its products and services. These statements are based on its current expectations. Actual results could differ materially from those provided in this release and Bio-IT World has no obligation to update such statements. There are numerous risks that have the potential to negatively impact its results, including the risks and uncertainties disclosed in its filing on Form 10-Q for the fiscal year ended April 30, 2026, which you can find here (a summary of risks which may impact its business can be found on pages 33 and 34), and in its subsequent SEC filings, which you can access at sec.gov.